Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLMARK: Aliskiren vs Losartan in Hypertensive LVH
NCT01176032Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aliskiren in hypertension (HTN) and left ventricular hypertrophy (LVH) (2 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in C-terminal Propeptide of Procollagen Type I at 36 weeks. Started Jun 2010; status: completed.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on NCT01176032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01176032.